03.02.2025 16:38:34

Boundless Bio Appoints Robert Doebele As Chief Medical Officer

(RTTNews) - Boundless Bio Inc. (BOLD), a San Diego-based clinical-stage oncology company, Monday announced the appointment of Robert Doebele as Chief Medical Officer.

The company has been advancing its BBI-355 Phase 1/2 POTENTIATE trial and prepares to select a development candidate for its Kinesin program.

Doebele brings extensive experience in precision oncology, having co-founded Rain Oncology, Inc., where he had previously served as Chief Scientific and Medical Officer.

BOLD is currently trading at $2.31 up 0.87 percent or $0.02 on the Nasdaq.

Nachrichten zu Audentes Therapeutics Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Audentes Therapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!